| Literature DB >> 30410368 |
Jiayu Zhou1, Shizhen Zhang2, Guoxiang Fu3, Zhengfu He1, Yong Xu1, Weiwen Ye1, Zhoumiao Chen1.
Abstract
BACKGROUND: Anaphase-promoting complex subunit 11 (APC11) plays an important role in gathering E2 and catalyzing ubiquitin-chain formation to support ubiquitination of substrates by acting as a catalytic core subunit of anaphase-promoting complex (APC/C). However, whether APC11 is implicated in the tumorigenesis of lung cancer is never known.Entities:
Keywords: APC11; cell proliferation; invasion; lung cancer; migration
Year: 2018 PMID: 30410368 PMCID: PMC6200086 DOI: 10.2147/OTT.S177252
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1The prognostic value of the mRNA expression of APC11 in www.kmplot.com. (A) Prognostic HRs of APC11 in all lung cancer. Survival curves of APC11 in lung adenocarcinoma (B) and lung squamous cell carcinoma (C).
Figure 2(A) Different expression levels of APC11 in several lung cancer cell lines were detected by Western blot. (B) The densitometric analysis of Western blot in (A).
Note: *P<0.05.
Figure 3(A) Growth rates were measured at the indicated times in si-Cont and si-APC11 lung cancer cells using Cell Counting Kit-8 assay. (B) Growth rate curves of Vector and Flag-APC11 transfected lung cancer cells. (C) Colony formation assay results of lung cancer cells transduced with si-Cont or si-APC11. (D) The results of colony formation assay are expressed as mean ± SD from triplicate experiments.
Note: *P<0.05.
Figure 4(A) Cell cycle analysis was performed in si-Cont and si-APC11 lung cancer cells using fluorescence-activated cell sorter (FACS). (B) Transwell migration and invasion assays were performed in lung cancer cells with or without APC11 silencing. (C) The results are expressed as mean ± SD from triplicate experiments.
Note: *P<0.05.
Figure 5(A) Hemotoxylin and eosin (HE) staining of normal lung tissues (NLTs) and lung tumor tissues (LTTs). Immunohistochemical analysis of APC11 in negative (−) and positive (+) normal lung NLTs and LTTs. (B) Kaplan–Meier OS analysis of APC11 expression for NSCLC. (C) Kaplan–Meier OS analysis of APC11 expression for lung adenocarcinoma patients. (D) Survival curves of APC11 expression for lung squamous cell carcinoma patients. (E) Multivariate COX analyses of APC11 for OS in lung adenocarcinoma patients.
Relationship between APC11 overexpression and clinicopathologic characteristics in NSCLCs
| Variables | APC11 | APC11 | |
|---|---|---|---|
| Sex | 0.443 | ||
| Female | 31 | 21 | |
| Male | 31 | 24 | |
| Age | 53+9.8 | 54.9+10.4 | 0.533 |
| Smoker | 0.086 | ||
| Former or current | 25 | 25 | |
| Never | 37 | 20 | |
| Tumor location | 0.744 | ||
| Right upper lobe | 25 | 13 | |
| Right middle lobe | 8 | 7 | |
| Right lower lobe | 12 | 12 | |
| Left upper lobe | 9 | 8 | |
| Left lower lobe | 8 | 5 | |
| Tumor size, mean±SD | 3.06+0.86 | 3.13+0.85 | 0.881 |
| Histology | 0.509 | ||
| Adenoca | 41 | 21 | |
| Seqcc | 21 | 16 | |
| Differentiation | 0.054 | ||
| Well | 22 | 22 | |
| Moderate | 21 | 18 | |
| Poor | 19 | 5 | |
| Pathologic stage | 0.640 | ||
| I | 23 | 13 | |
| II | 27 | 21 | |
| IIIA | 12 | 11 |